Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 4/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | PNMT | P11086 | 1/20 | 0.34 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 2/20 | 0.30 |
| ▸ | HTR2C | P28335 | 2/20 | 0.30 |
| ▸ | HTR2B | P41595 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6725684 | 0.89 | LMNA (0.41) | MAPTLMNAHTTBLMAHR | |
| SCHEMBL3524411 | 0.81 | LMNA (0.50) | MAPTLMNAHTTBLMAHR | |
| SCHEMBL30034940 | 0.81 | LMNA (0.50) | MAPTLMNAHTTBLMAHR | |
| SCHEMBL97599 | 0.78 | — | — | |
| SCHEMBL3838626 | 0.78 | MAPT (0.38) | MAPTLMNATDP1 | |
| SCHEMBL11816254 | 0.76 | AHR (0.43) | MAPTLMNAHTTBLMAHR | |
| SCHEMBL3519647 | 0.76 | MAPT (0.48) | MAPTLMNAHTTBLMAHR | |
| SCHEMBL95231 | 0.74 | KCNH2 (0.34) | MAPTKCNH2CYP3A4 | |
| SCHEMBL11519567 | 0.74 | KCNH2 (0.34) | KCNH2 | |
| SCHEMBL11521104 | 0.74 | ALDH1A1 (0.43) | MAPTKCNH2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7078568-B2 | Phosphine compounds, transition metal complexes with the compounds contained as ligands therein, and asymmetric synthesis catalysts containing the complexes | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-07-18 | — | — | US | disclosed |
| US-6987202-B2 | Phosphine compounds, transition metal complexes with the compounds contained as ligands therein, and asymmetric synthesis catalysts containing the complexes | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-01-17 | — | — | US | disclosed |
| US-20050288531-A1 | Phosphine compounds, transition metal complexes with the compounds contained as ligands therein, and asymmetric synthesis catalysts containing the complexes | SHIMIZU HIDEO | 2005-12-29 | — | — | US | disclosed |
| EP-1419815-A1 | Phosphine compounds, transition metal complexes with the compounds contained as ligands therein, and asymmetric synthesis catalysts containing the complexes | Takasago International Corporation (JP) | 2004-05-19 | — | — | EP | disclosed |
| US-20040092388-A1 | Phosphine compounds, transition metal complexes with the compounds contained as ligands therein, and asymmetric synthesis catalysts containing the complexes | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288531-A1 | Phosphine compounds, transition metal complexes with the compounds contained as ligands therein, and asymmetric synthesis catalysts containing the complexes | PHOSPHO1, PRMT1, PRMT9 | MAPT 3919/4885LMNA 4721/4885HTT 3803/4885 |
| US-20040092388-A1 | Phosphine compounds, transition metal complexes with the compounds contained as ligands therein, and asymmetric synthesis catalysts containing the complexes | PHOSPHO1, INPP5B, PRMT1 | MAPT 3904/4885LMNA 4667/4885HTT 4217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.